Sandbox ID Musculoskeletal: Difference between revisions

← Older edit Newer edit →

VisualWikitext

Revision as of 20:21, 28 July 2015

Bursitis

Olecranon bursitis or prepatellar bursitis ^[1]

1. Staphylococcus aureus, methicillin-susceptible (MSSA)

Preferred regimen: Nafcillin 2 g IV q4h OR Oxacillin 2 g IV q4h OR Dicloxacillin 500 mg PO qid

2. Staphylococcus aureus, methicillin-resistant (MRSA)

Preferred regimen: Vancomycin 1 g IV q12h OR Linezolid 600 mg PO qd

Note: Initially aspirate q24h and treat for a minimum of 2–3 weeks.

Osteomyelitis, candidal

Osteomyelitis, candidal ^[2]

Preferred regimen: Fluconazole 400 mg (6 mg/kg) PO qd for 6–12 months OR lipid formulation of Amphotericin B 3–5 mg/kg PO qd for several weeks, then Fluconazole for 6–12 months
Alternative regimen (1): Anidulafungin 200 mg loading dose, then 100 mg/day PO OR Caspofungin 70mg loading dose, then 50 mg/day PO OR Micafungin 100 mg/day PO, then Fluconazole for 6–12 months
Alternative regimen (2): Amphotericin B deoxycholate 0.5–1 mg/kg PO qd for several weeks, then Fluconazole for 6–12 months

NOTE: Duration of therapy usually is prolonged (6–12 months); Surgical debridement is frequently necessary

Osteomyelitis, chronic

Chronic Osteomyelitis in Adults – Pathogen-Based Therapy ^[3]

^[4]

1. OSSA

Preferred regimen: Oxacillin 1.5–2 g IV q4h for 4–6 wk OR Cefazolin 1–2 g IV q8h for 4–6 wk
Alternative regimen (1): Vancomycin 15 mg/kg IV q12h for 4–6 wk
Alternative regimen (2): Oxacillin 1.5–2 g IV q4h for 4–6 wk AND Rifampin 600 mg PO qd

2. ORSA

Preferred regimen: Vancomycin 15 mg/kg IV q12h for 4–6 wk OR Daptomycin 6 mg/kg IV q24h
Alternative regimen (1): Linezolid 600 mg PO/IV q12h for 6 wk ± Rifampin 600–900 mg PO qd
Alternative regimen (2): Levofloxacin 500–750 mg PO/IV daily ± Rifampin 600–900 mg PO qd

3. Penicillin-sensitive Streptococcus

Preferred regimen: Penicillin G 20 MU/day IV continuously or q4h for 4–6 wk OR Ceftriaxone 1–2 g IV/IM q24h for 4–6 wk OR Cefazolin 1–2 g IV q8h for 4–6 wk
Alternative regimen: Vancomycin 15 mg/kg IV q12h for 4–6 wk

4. Enterococcus or Streptococcus (MIC≥0.5 μg/mL) or Abiotrophia or Granulicatella

Preferred regimen: Penicillin G 20 MU/day IV continuously or q4h for 4–6 wk ± Gentamicin 1 mg/kg IV/IM q8h for 1–2 wk OR Ampicillin 12 g/day IV continuously or q4h for 4–6 wk ± Gentamicin 1 mg/kg IV/IM q8h for 1–2 wk
Alternative regimen: Vancomycin 15 mg/kg IV q12h for 4–6 wk ± Gentamicin 1 mg/kg IV/IM q8h for 1–2 wk

5. Enterobacteriaceae

Preferred regimen: Ceftriaxone 1–2 g IV/IM q24h for 4–6 wk OR Ertapenem 1 g IV q24h
Alternative regimen: Levofloxacin 500–750 mg PO q24h OR Ciprofloxacin 500–750 mg PO q12h for 4–6 wk

Pseudomonas aeruginosa

6. Preferred regimen: Cefepime 2 g IV q12h OR Meropenem 1 g IV q8h OR Imipenem 500 mg IV q6h for 4–6 wk
Alternative regimen: Ciprofloxacin 750 mg PO q12h OR Ceftazidime 2 g IV q8h for 4–6 wk

Chronic Osteomyelitis in Children – Pathogen-Based Therapy

Group A beta-hemolytic Streptococcus, Haemophilus influenzae type b, andStreptococcus pneumoniae

Preferred regimen: Ampicillin 150–200 mg/kg/day administered in 4 equal doses OR Amoxicillin 150–200 mg/kg/day administered in 4 equal doses
Alternative regimen: Chloramphenicol 75 mg/kg/day administered in 3 equal doses

Osteomyelitis, contiguous with vascular insufficiency

Osteomyelitis, contiguous with vascular insufficiency ^[5]

Note (1): Debride overlying ulcer and send bone specimen for histology and culture.
Note (2): No empiric antimicrobial therapy unless acutely ill.
Note (3): Antibiotic therapy should be based on culture results and treat for 6 weeks.
Note (4): Revascularize if possible.

Osteomyelitis, diabetic foot

1. Chronic Infection or Recent Antibiotic Use ^[6]

Preferred regimen: Levofloxacin 750 mg IV/PO q24h OR Cefoxitin 1 g IV q4h (or 2 g IV q6–8h) OR Ceftriaxone 1–2 g/day IV/IM q12–24h OR Ampicillin–Sulbactam 1.5–3 g IV/IM q6h OR Moxifloxacin 400 mg IV/PO q24h OR Ertapenem 1 g IV/IM q24h OR Tigecycline 100 mg IV, then 50 mg IV q12h (active against MRSA) OR Imipenem–Cilastatin 0.5–1 g IV q6–8h (Not active against MRSA; consider when ESBL-producing pathogens suspected)
Alternative regimen (1): Levofloxacin 750 mg IV/PO q24h AND Clindamycin 150–300 mg PO qid
Alternative regimen (2): Ciprofloxacin 600–1200 mg/day IV q6–12h AND Clindamycin 150–300 mg PO qid
Alternative regimen (3): Ciprofloxacin 1200–2700 mg IV q6–12h (for more severe cases) AND Clindamycin 150–300 mg PO qid

2. High Risk for MRSA

Preferred regimen: Linezolid 600 mg IV/PO q12h OR Daptomycin 4 mg/kg IV q24h OR Vancomycin 15–20 mg/kg IV q8–12h (trough: 10–20 mg/L)

High Risk for Pseudomonas aeruginosa

Preferred regimen: Piperacillin–Tazobactam 3.375 g IV q6–8h

3. Polymicrobial Infection

Preferred regimen: (Vancomycin 15–20 mg/kg IV q8–12h (trough: 10–20 mg/L) OR Linezolid 600 mg IV/PO q12h OR Daptomycin 4 mg/kg IV q24h) AND (Piperacillin–Tazobactam 3.375 g IV q6–8h OR Imipenem–Cilastatin 0.5–1 g IV q6–8h OR Ertapenem 1 g IV/IM q24h OR Meropenem 1 g IV q8h)
Alternative regimen: (Vancomycin 15–20 mg/kg IV q8–12h (trough: 10–20 mg/L) OR Linezolid 600 mg IV/PO q12h OR Daptomycin 4 mg/kg IV q24h) AND (Ceftazidime 2 g IV q8h OR Cefepime 2 g IV q8h OR Aztreonam 2 g IV q6–8h) AND Metronidazole 15 mg/kg IV, then 7.5 mg/kg IV q6h

Osteomyelitis, foot bone

Foot bone osteomyelitis due to nail through tennis shoe ^[7]

Preferred regimen: Ciprofloxacin 750 mg po bid OR Levofloxacin 750 mg po q24h
Alternative regimen: Ceftazidime 2 gm IV q8h OR Cefepime 2 gm IV q12h

Osteomyelitis, foot puncture wound

Long bone, post-internal fixation of fracture ^[8]

Preferred regimen: Vancomycin 1 gm IV q12h AND (Ceftazidime OR Cefepime)

Alternative regimen (1): Linezolid 600 mg IV/po bid^NAI AND Ceftazidime
Alternative regimen (2): Linezolid 600 mg IV/po bid^NAI AND Cefepime

NOTE: If susceptible Gm-neg. bacillus, Ciprofloxacin 750 mg po bid OR Levofloxacin 750 mg po qd

Osteomyelitis, hematogenous

1. Empiric therapy ^[9]

1.1 Adult (>21 yrs)

1.1.1 MRSA possible

Preferred regimen: Vancomycin 1 gm IV q12h (if over 100 kg, 1.5 gm IV q12h)

1.1.2 MRSA unlikely

Preferred regimen: Nafcillin OR Oxacillin 2 gm IV q4h

1.2. Children (>4 mos.)-Adult

1.2.1 MRSA possible

Preferred regimen: Vancomycin 40 div q6–8h

1.2.2 MRSA unlikely

Preferred regimen: Nafcillin OR Oxacillin 37 q6h (to max. 8–12 gm per day)

NOTE: Add Ceftazidime 50 q8h or Cefepime 150 div q8h if Gm-neg. bacilli on Gram stain

1.3. Newborn (<4 mos.)

1.3.1 MRSA possible

Preferred regimen: Vancomycin AND (Ceftazidime 2 gm IV q8h or Cefepime 2 gm IV q12h)

1.3.2 MRSA unlikely

Preferred regimen: (Nafcillin OR Oxacillin) AND (Ceftazidime OR Cefepime)

2. Specific therapy

2.1 MSSA

Preferred regimen: Nafcillin OR Oxacillin 2 gm IV q4h OR Cefazolin 2 gm IV q8h
Alternative regimen: Vancomycin 1 gm IV q12h (if over 100 kg, 1.5 gm IV q12h)

2.2 MRSA

Preferred regimen: Vancomycin 1 gm IV q12h
Alternative regimen: Linezolid 600 mg q12h IV/po ± Rifampin 300 mg po/IV bid

Osteomyelitis, hemoglobinopathy

. Osteomyelitis, hemoglobinopathy ^[10]

Preferred regimen: Ciprofloxacin 400 mg IV q12h
Alternative regimen: Levofloxacin 750 mg IV q24h

Osteomyelitis, spinal implant

1. Onset within 30 days ^[11]

Preferred regimen: Culture, treat & then suppress until fusion occurs

2. Onset after 30 days

Preferred regimen: Remove implant, culture & treat

Osteomyelitis, vertebral

Vertebral Osteomyelitis – Pathogen-Based Therapy ^[12] ^[13]

1. OSSA or coagulase-negative staphylococci

Preferred regimen: Oxacillin 2 g IV q6h OR Cefazolin 1–2 g IV q8h
Alternative regimen: Levofloxacin 750 mg PO qd AND Rifampin 300 mg PO bid

2. ORSA

Preferred regimen: Vancomycin 1 g IV q12h
Alternative regimen (1): Daptomycin ≥ 6 mg/kg IV q24h
Alternative regimen (2): Levofloxacin 500–750 mg PO/IV daily AND Rifampin 600–900 mg PO qd

3. Streptococcus

Preferred regimen: Penicillin G 5 MU IV q6h
Alternative regimen: Ceftriaxone 2 g IV q24h

4. Enterobacteriaceae, quinolone-susceptible

Preferred regimen: Ciprofloxacin 750 mg PO q12h
Alternative regimen: Ceftriaxone 2 g IV q24h

5. Enterobacteriaceae, quinolone-resistant

Preferred regimen: Imipenem 500 mg IV q6h

6. Pseudomonas aeruginosa

Preferred regimen: Cefepime 2 g IV q8h OR Ceftazidime 2 g IV q8h x 2–4 wk, followed by Ciprofloxacin 750 mg PO bid
Alternative regimen: Piperacillin–Tazobactam 750 mg PO q12h x 2–4 wk, followed by Ciprofloxacin 750 mg PO bid

7. Anaerobes

Preferred regimen: Piperacillin–Tazobactam 750 mg PO q12h x 2–4 wk, followed by Ciprofloxacin 750 mg PO bid
Alternative regimen (1): Penicillin G 5 MU IV q6h OR Ceftriaxone 2 g IV q24h (against gram-positive anaerobes)
Alternative regimen (2): Metronidazole 500 mg PO tid (against gram-negative anaerobes)

Osteomyelitis, sternal

Osteomyelitis, sternal ^[14]

Preferred regimen: Vancomycin 1 gm IV q12h (If over 100kg, 1.5 gm IV q12h)
Alternative regimen: Linezolid 600 mg po/IV^NAI bid

Osteonecrosis of the jaw

1. Bacterial Infection ^[15]

Preferred regimen: Penicillin VK 500 mg PO q6–8h for 7–10 days (maintenance: 500 mg PO bid) OR Amoxicillin 500 mg PO q8h for 7–10 days (maintenance: 500 mg PO bid)
Alternative regimen: Clindamycin 150–300 mg PO qid OR Doxycycline 100 mg PO qd OR Erythromycin 400 mg PO tid OR Azithromycin 500 mg PO for 1 dose, then 250 mg PO qd for 4 days OR Levofloxacin 500 mg PO qd OR Moxifloxacin 400 mg PO qd

2. Fungal Infection

Preferred regimen: Nystatin oral suspension 5–15 mL swish qid OR Fluconazole 200 mg PO qd, then 100 mg q24h OR Clotrimazole 10 mg PO tid for 7–10 days

3. Viral Infection

Preferred regimen: Acyclovir 400 mg PO bid OR Valacyclovir 0.5–2.0 g PO bid

Reactive arthritis, post-streptococcal arthritis

Reactive arthritis, post-streptococcal arthritis ^[16]

Preferred regimen: Treat strep pharyngitis and then NSAIDs (Prednisone needed in some patients)

Reactive arthritis, Reiter's syndrome

Reactive arthritis, Reiter's syndrome ^[17]

Preferred regimen: Only treatment is non-steroidal anti-inflammatory drugs

Septic arthritis, Brucella melitensis

Septic arthritis, Brucella melitensis ^[18]

Preferred Regimen: Doxycycline 100 mg PO bid for ≥ 6 weeks AND Streptomycin 15 mg/kg IM qd for 2–3 weeks OR Rifampin 600–900 mg qd for ≥ 6 weeks
Alternative Regimen: Doxycycline 100 mg PO bid for ≥ 6 weeks AND Gentamicin 5 mg/kg IV qd for 7 days

Septic arthritis, candidal

Septic arthritis, candidal ^[2]

Preferred regimen: Fluconazole 400 mg (6 mg/kg) daily for at least 6 weeks OR lipid formulation of Amphotericin B 3–5 mg/kg daily for several weeks, then Fluconazole to completion
Alternative regimen: Anidulafungin 200-mg loading dose, then 100 mg/day OR Caspofungin 70-mg loading dose, then 50 mg/day OR Micafungin 100 mg/day OR Amphotericin B deoxycholate 0.5–1 mg/kg daily for several weeks then Fluconazole to completion
NOTE: Duration of therapy usually is for at least 6 weeks, but few data are available; Surgical debridement is recommended for all cases; For infected prosthetic joints, removal is recommended for most cases.

Septic arthritis, gonococcal

Septic arthritis, gonococcal ^[19]

Preferred regimen: Ceftriaxone 1 g intramuscularly IM/IV every 24 h
Alternative regimen: Cefotaxime 1 g IV every 8 hours OR Ceftizoxime 1 g IV every 8 hours
NOTE: The tetracyclines (except in pregnant women) or penicillins may be used if the infecting organism is proven to be susceptible; Penicillin allergies should be given Spectinomycin (2 g IV every 12 h);Alternative antibiotics in the β-lactam-allergic patient may be Ciprofloxacin (500 mg IV every 12 h) or Ofloxacin (400 mg IV every 12 h)
Pediatric regimen: (>45 kg) single daily dose of Ceftriaxone (50 mg/kg and a maximum dose of 2 g, IM or IV) for 10 to 14 days; (<45 kg) Ceftriaxone (50 mg/kg and a maximum dose of 1 g, IM or IV in a single daily dose for 7 days)

Septic arthritis, Gram-negative bacilli

Septic arthritis, Gram-negative bacilli ^[20]

Preferred regimen: Ceftazidime 2 g IV q8h OR Cefepime 2 g IV q8–12h OR Piperacillin-Tazobactam 4.5 g IV q6h
Alternative regimen: Aztreonam 2 g IV q8h OR Imipenem 500 mg IV q6h OR Meropenem 1 g IV q8h {or}} Doripenem 500 mg IV q8h OR Carbapenems

Septic arthritis, Histoplasmosis

Septic arthritis, histoplasmosis^[21]

1. Mild disease

Preferred regimen: Nonsteroidal anti-inflammatory drug

2. Severe disease

Preferred regimen: Prednisone 0.5–1.0 mg/kg/day (maximum: 80 mg daily) in tapering doses over 1–2 weeks AND Itraconazole 200 mg tid for 3 days, followed by qd or bid for 6–12 weeks

Septic arthritis, Lyme disease

Septic arthritis, Lyme disease ^[22]

1. Patients without clinical evidence of neurologic disease

Preferred regimen: Doxycycline 100 mg twice per day OR Amoxicillin 500 mg 3 times per day OR Cefuroxime Axetil 500 mg twice per day for 28 days
Pediatric regimen: Amoxicillin 50 mg/kg per day in 3 divided doses maximum of 500 mg per dose OR Cefuroxime Axetil 30 mg/kg per day in 2 divided doses maximum of 500 mg per dose OR (if the patient is ≥8 years of age) Doxycycline 4 mg/ kg per day in 2 divided doses (maximum of 100 mg per dose)

2. Patients with arthritis and objective evidence of neurologic disease

Preferred regimen: Ceftriaxone administered parenterally for 2–4 weeks
Alternative regimen: Cefotaxime OR Penicillin G administered parenterally
Pediatric regimen: Ceftriaxone OR Cefotaxime OR Penicillin G administered intravenously

NOTE (1): For patients who have persistent or recurrent joint swelling after a recommended course of oral antibiotic therapy, we recommend re-treatment with another 4-week course of oral antibiotics or with a 2–4-week course of Ceftriaxone IV
NOTE (2): If patients have no resolution of arthritis despite intravenous therapy and if PCR results for a sample of synovial fluid (and synovial tissue if available) are negative, symptomatic treatment is recommended, which consist of nonsteroidal anti-inflammatory agents, intra-articular injections of corticosteroids, or disease-modifying antirheumatic drugs (DMARDs), such as Hydroxychloroquine.

Septic arthritis, Mycobacterium tuberculosis

Septic arthritis, Mycobacterium tuberculosis^[23]

1. Septic arthritis caused by susceptible Mycobacterium tuberculosis

1.1 Adults

1.1.1 Intensive phase

Preferred regimen: Isoniazid 5 mg/kg (max: 300 mg) for 2 months AND Rifampin 10 mg/kg (max: 600 mg) for 2 months AND Pyrazinamide 15–30 mg/kg (max: 2 g) for 2 months AND Ethambutol 15–20 mg/kg (max: 1 g) for 2 months

1.1.2 Continuation phase

Preferred regimen: Isoniazid 5 mg/kg (max: 300 mg) for 7 months AND Rifampin 10 mg/kg (max: 600 mg) for 7 months

1.2 Pediatric

1.2.1 Intensive phase

Preferred regimen: Isoniazid 10–15 mg/kg (max: 300 mg) for 2 months AND Rifampin 10–20 mg/kg (max: 600 mg) for 2 months AND Pyrazinamide 15–30 mg/kg (max: 2 g) for 2 months AND Ethambutol 15–20 mg/kg (max: 1 g) for 2 months

1.2.2 Continuation phase

Preferred regimen: Isoniazid 10–15 mg/kg (max: 300 mg) for 7 months AND Rifampin 10–20 mg/kg (max: 600 mg) for 7 months

2. Specific considerations

2.1 Pregnancy and breastfeeding

With the exception of streptomycin, the first line anti-TB drugs are safe for use in pregnancy: Streptomycin is ototoxic to the fetus and should not be used during pregnancy.
After active TB in the baby is ruled out, the baby should be given 6 months of isoniazid preventive therapy, followed by BCG vaccination.
Pyridoxine supplementation is recommended for all pregnant or breastfeeding women taking isoniazid.

2.2 Liver disorders

Two hepatotoxic drugs (rather than the three in the standard regimen):

9 months of Isoniazid AND Rifampicin AND Ethambutol (until or unless Isoniazid susceptibility is documented).
2 months of Isoniazid AND Rifampicin AND Streptomycin AND Ethambutol, followed by 6 months of Isoniazid AND Rifampicin.
6–9 months of Rifampicin AND [[Pyrazinamide}} AND Ethambutol.

One hepatotoxic drug:

2 months of Isoniazid AND Ethambutol AND [[Streptomycin}}, followed by 10 months of Isoniazid AND Ethambutol.

No hepatotoxic drugs:

18–24 months of Streptomycin AND Ethambutol AND a Fluoroquinolone.

2.3 Renal failure and severe renal insufficiency

The recommended initial TB treatment regimen for patients with renal failure or severe renal insufficiency is 2 months of isoniazid, rifampicin, pyrazinamide and ethambutol, followed by 4 months of isoniazid and rifampicin.
There is significant renal excretion of ethambutol and metabolites of pyrazinamide, and doses should therefore be adjusted.
Three times per week administration of these two drugs at the following doses is recommended: pyrazinamide (25 mg/kg), and ethambutol (15 mg/kg)
While receiving isoniazid, patients with severe renal insufficiency or failure should also be given pyridoxine in order to prevent peripheral neuropathy.
Because of an increased risk of nephrotoxicity and ototoxicity, Streptomycin should be avoided in patients with renal failure. If Streptomycin must be used, the dosage is 15 mg/kg, two or three times per week, to a maximum of 1 gram per dose, and serum levels of the drug should be monitored.

2.4 Previously treated patients in settings with rapid DST

TB patients whose treatment has failed or other patient groups with high likelihood of multidrug-resistant TB (MDR) should be started on an empirical MDR regimen.
TB patients returning after defaulting or relapsing from their first treatment course may receive the retreatment regimen containing first-line drugs 2HRZES/1HRZE/5HRE if country-specific data show low or medium levels of MDR in these patients or if such data are not available.

2.5 TB treatment in people living with HIV

TB patients with known positive HIV status and all TB patients living in HIV prevalent settings should receive daily TB treatment at least during the intensive phase.
For the continuation phase, the optimal dosing frequency is also daily for these patients.
If a daily continuation phase is not possible for these patients, three times weekly dosing during the continuation phase is an acceptable alternative.
It is recommended that TB patients who are living with HIV should receive at least the same duration of TB treatment as HIV-negative TB patients.

Septic arthritis, pneumococcal

Septic arthritis, post-intraarticular injection

Septic arthritis, post-intraarticular injection ^[24]

NO empiric therapy.

Septic arthritis, prosthetic joint infection

Septic arthritis, prosthetic joint infection (device-related osteoarticular infections) ^[25]

1. Empiric antimicrobial therapy

It is preferable to delay antibiotic therapy until specimens for culture are obtained by joint aspiration, joint debridement, and/or prosthesis removal.

2. Pathogen-directed antimicrobial therapy

2.1 Staphylococcus aureus, methicillin-susceptible (MSSA)

Preferred regimen: Nafcillin 2 g IV q4–6h OR Oxacillin 2 g IV q4–6h
Alternative regimen: Cefazolin 1–2 g IV q8h OR Ceftriaxone 2 g IV q24h
Alternative regimen (if allergic to penicillins): Clindamycin 900 mg IV q8h OR Vancomycin 15–20 mg/kg IV q8–12 hours, not to exceed 2 g per dose

2.2 Staphylococcus, methicillin-resistant (MRSA)

2.2.1 Early-onset (< 2 months after surgery) or acute hematogenous prosthetic joint infections involving a stable implant with short duration (< 3 weeks) of symptoms and debridement (but device retention)

Preferred regimen: Vancomycin AND Rifampin 600 mg PO qd or 300–450 mg PO bid for 2 weeks
Alternative regimen: (Daptomycin 6 mg/kg IV q24h OR Linezolid 600 IV q8h) AND Rifampin 600 mg PO qd or 300–450 mg PO bid for 2 weeks
Note: The above regimen should be followed by Rifampin plus a fluoroquinolone, TMP/SMX, a tetracycline or Clindamycin for 3 or 6 months for hips and knees, respectively.

2.2.2 Early-onset spinal implant infections (< 30 days after surgery), or implants in an actively infected site

Initial parenteral therapy plus Rifampin followed by prolonged oral therapy is recommended.
Long-term oral suppressive antibiotics (eg, TMP-SMX, a tetracycline, a fluoroquinolone [which should be given in conjunction with Rifampin due to the potential emergence of fluoroquinolone resistance)

2.3 Streptococci, beta-hemolytic

Preferred regimen: Penicillin 12–18 MU/day IV q6h OR Ampicillin 2 g IV q6h OR Ceftriaxone 1–2 g IV q24h
Alternative regimen (allergic to penicillin): Clindamycin 900 mg IV q8h OR Vancomycin 15–20 mg/kg q8–12h, not to exceed 2 g per dose

2.4 Enterococci

2.4.1 Monotherapy

Preferred regimen (1): Ampicillin 6 to 12 g per 24 hours in four to six equally divided doses
Preferred regimen (2): Penicillin G 18 to 30 million units per 24 hours either continuously or in six equally divided doses
Preferred regimen (3): Vancomycin 15 to 20 mg/kg/dose every 8 to 12 hours, not to exceed 2 g per dose

2.4.2 Combination therapy (one of the monotherapy agents, and one of the following agents)

Preferred regimen (1): Gentamicin 1 mg/kg IV q8h
Preferred regimen (2): Streptomycin 7.5 mg/kg IV q12h
Preferred regimen (3): Ampicillin 2 g/day IV q6h AND Ceftriaxone 2 g IV q12h

2.5 Gram-negative bacilli

Patients susceptible to fluoroquinolones

Preferred regimen: Ciprofloxacin 500 to 750 mg bid

2.5.1 P. aeruginosa

Preferred regimen: Cefepime 2 g intravenously every 12 hours OR Meropenem 1 g intravenously every 8 hours
Alternative regimen (1): Ciprofloxacin 750 mg orally every 12 hours Ceftazidime 2 g intravenously every 8 hours (alternative)
Alternative regimen (2): Ceftazidime 2 g intravenously every 8 hours

2.6 Anaerobes

2.6.1Propionibacterium acnes

Preferred regimen: Penicillin 24 million units intravenously every 24 hours given in six equally divided doses or as continuous infusion OR Ceftriaxone 1 to 2 g intravenously once daily
Alternative regimen: Vancomycin OR Clindamycin

2.6.2 Not Propionibacterium acnes
Preferred regimen: Metronidazole 500 mg orally three times a day.

2.7 Mycobacterium tuberculosis

Preferred regimen: see (Septic arthritis, Mycobacterium tuberculosis)

2.8 Fungi

Preferred regimen: see (Septic arthritis, candidal)

2.9 Culture negative

Preferred regimen: Vancomycin AND Ciprofloxacin OR Cefazolin AND Ciprofloxacin

Septic arthritis, staphylococcal

1.Staphylococcus aureus (methicillin-resistant) ^[26]^[27]Invalid parameter in <ref> tag

Preferred regime: Vancomycin 15–20 mg/kg IV q8–12h
Alternative regimen (1): Daptomycin 6 mg/kg IV q24h in adults
Alternative regimen (2): Linezolid 600 mg PO/IV q12h
Alternative regimen (3): Clindamycin 600 mg PO/IV q8h
Alternative regimen (4): TMP-SMX 3.5–4.0 mg/kg PO/IV q8–12h
Pediatric regimen: Vancomycin 15 mg/kg IV q6h OR Daptomycin 6–10 mg/kg IV q24h OR Linezolid 10 mg/kg PO/IV q8h OR Clindamycin 10–13 mg/kg/dose PO/IV q6–8h

2. Staphylococcus aureus (methicillin-susceptible)

Preferred regimen: Nafcillin 2 g IV q6h OR Clindamycin 900 mg IV q8h
Alternative regimen: Cefazolin 0.25–1 g IV/IM q6–8h OR Vancomycin 500 mg IV q6h or 1 g IV q12h

3. Staphylococcus epidermidis (methicillin-resistant)

Preferred regimen: Vancomycin 500 mg IV q6h or 1 g IV q12h OR Linezolid 600 mg IV q12h
Alternative regimen: TMP-SMX 3.5–4.0 mg/kg PO/IV q8–12h (TMP component) OR Minocycline 200 mg PO x 1 dose, then 100 mg PO q12h AND Rifampin 300–600 mg PO/IV q12h

4. Staphylococcus epidermidis (methicillin-susceptible)

Preferred regimen: Nafcillin 2 g IV q6h OR Clindamycin 900 mg IV q8h
Alternative regimen: Cefazolin 0.25–1 g IV/IM q6–8h OR Vancomycin 500 mg IV q6h or 1 g IV q12h

Septic arthritis, streptococcal

1. Streptococcus agalactiae ^[28]

Preferred regimen: Penicillin G 2 MU IV/IM q4h OR Ampicillin 2 g IV q6h
Alternative regimen: Clindamycin 600–1200 mg/day IV/IM q6–12h OR Cefazolin 0.25–1 g IV/IM q6–8h

2. Streptococcus pyogenes

Preferred regimen: Penicillin G 2 MU IV/IM q4h OR Ampicillin 2 g IV q6h
Alternative regimen: Clindamycin 600–1200 mg/day IV/IM q6–12h OR Cefazolin 0.25–1 g IV/IM q6–8h

References

↑ Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
↑ ^2.0 ^2.1 Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE; et al. (2009). "Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America". Clin Infect Dis. 48 (5): 503–35. doi:10.1086/596757. PMID 19191635.
↑ Spellberg B, Lipsky BA (2012). "Systemic antibiotic therapy for chronic osteomyelitis in adults". Clin Infect Dis. 54 (3): 393–407. doi:10.1093/cid/cir842. PMC 3491855. PMID 22157324.CS1 maint: PMC format (link)
↑ http://www.uptodate.com/contents/search?search=chronic+osteomyelitis&sp=0&searchType=PLAIN_TEXT&source=USER_INPUT&searchControl=TOP_PULLDOWN&searchOffset=. Missing or empty |title= (help)
↑ Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
↑ Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG; et al. (2013). "2012 infectious diseases society of america clinical practice guideline for the diagnosis and treatment of diabetic foot infections". J Am Podiatr Med Assoc. 103 (1): 2–7. PMID 23328846.
↑ Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
↑ Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
↑ Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
↑ Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
↑ Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
↑ Gentry LO (1991). "Oral antimicrobial therapy for osteomyelitis". Ann Intern Med. 114 (11): 986–7. PMID 2024868.
↑ Marschall J, Bhavan KP, Olsen MA, Fraser VJ, Wright NM, Warren DK (2011). "The impact of prebiopsy antibiotics on pathogen recovery in hematogenous vertebral osteomyelitis". Clin Infect Dis. 52 (7): 867–72. doi:10.1093/cid/cir062. PMC 3106232. PMID 21427393.
↑ Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
↑ Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
↑ Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
↑ Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
↑ Corbel, Michael (2006). Brucellosis in humans and animals. Geneva: World Health Organization. ISBN 9241547138.
↑ Shirtliff ME, Mader JT (2002). "Acute septic arthritis". Clin Microbiol Rev. 15 (4): 527–44. PMC 126863. PMID 12364368.CS1 maint: PMC format (link)
↑ Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
↑ Wheat LJ, Freifeld AG, Kleiman MB, Baddley JW, McKinsey DS, Loyd JE; et al. (2007). "Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America". Clin Infect Dis. 45 (7): 807–25. doi:10.1086/521259. PMID 17806045.
↑ Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS; et al. (2006). "The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America". Clin Infect Dis. 43 (9): 1089–134. doi:10.1086/508667. PMID 17029130.
↑ Treatment of Tuberculosis: Guidelines. WHO Guidelines Approved by the Guidelines Review Committee (4th ed.). Geneva: World Health Organization. 2010. ISBN 9789241547833. PMID 23741786. Retrieved 2015-06-08.
↑ Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.
↑ Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM; et al. (2013). "Executive summary: diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America". Clin Infect Dis. 56 (1): 1–10. doi:10.1093/cid/cis966. PMID 23230301.
↑ Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ; et al. (2011). "Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children". Clin Infect Dis. 52 (3): e18–55. doi:10.1093/cid/ciq146. PMID 21208910.
↑ Sharff KA, Richards EP, Townes JM (2013). "Clinical management of septic arthritis". Curr Rheumatol Rep. 15 (6): 332. doi:10.1007/s11926-013-0332-4. PMID 23591823.
↑ "Clinical Management of Septic Arthritis" (PDF).

[1] Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.

[pmid19191635-2] 2.0 ^2.1 Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE; et al. (2009). "Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America". Clin Infect Dis. 48 (5): 503–35. doi:10.1086/596757. PMID 19191635.

[pmid22157324-3] Spellberg B, Lipsky BA (2012). "Systemic antibiotic therapy for chronic osteomyelitis in adults". Clin Infect Dis. 54 (3): 393–407. doi:10.1093/cid/cir842. PMC 3491855. PMID 22157324.CS1 maint: PMC format (link)

[Uptodate-4] ttp://www.uptodate.com/contents/search?search=chronic+osteomyelitis&sp=0&searchType=PLAIN_TEXT&source=USER_INPUT&searchControl=TOP_PULLDOWN&searchOffset=. Missing or empty |title= (help)

[5] Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.

[pmid23328846-6] Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG; et al. (2013). "2012 infectious diseases society of america clinical practice guideline for the diagnosis and treatment of diabetic foot infections". J Am Podiatr Med Assoc. 103 (1): 2–7. PMID 23328846.

[7] Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.

[8] Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.

[9] Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.

[10] Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.

[11] Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.

[pmid2024868-12] Gentry LO (1991). "Oral antimicrobial therapy for osteomyelitis". Ann Intern Med. 114 (11): 986–7. PMID 2024868.

[pmid21427393-13] Marschall J, Bhavan KP, Olsen MA, Fraser VJ, Wright NM, Warren DK (2011). "The impact of prebiopsy antibiotics on pathogen recovery in hematogenous vertebral osteomyelitis". Clin Infect Dis. 52 (7): 867–72. doi:10.1093/cid/cir062. PMC 3106232. PMID 21427393.

[14] Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.

[15] Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.

[16] Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.

[17] Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.

[18] Corbel, Michael (2006). Brucellosis in humans and animals. Geneva: World Health Organization. ISBN 9241547138.

[pmid12364368-19] Shirtliff ME, Mader JT (2002). "Acute septic arthritis". Clin Microbiol Rev. 15 (4): 527–44. PMC 126863. PMID 12364368.CS1 maint: PMC format (link)

[20] Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.

[pmid17806045-21] Wheat LJ, Freifeld AG, Kleiman MB, Baddley JW, McKinsey DS, Loyd JE; et al. (2007). "Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America". Clin Infect Dis. 45 (7): 807–25. doi:10.1086/521259. PMID 17806045.

[pmid17029130-22] Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS; et al. (2006). "The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America". Clin Infect Dis. 43 (9): 1089–134. doi:10.1086/508667. PMID 17029130.

[23] Treatment of Tuberculosis: Guidelines. WHO Guidelines Approved by the Guidelines Review Committee (4th ed.). Geneva: World Health Organization. 2010. ISBN 9789241547833. PMID 23741786. Retrieved 2015-06-08.

[24] Gilbert, David (2015). The Sanford guide to antimicrobial therapy. Sperryville, Va: Antimicrobial Therapy. ISBN 978-1930808843.

[pmid23230301-25] Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM; et al. (2013). "Executive summary: diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America". Clin Infect Dis. 56 (1): 1–10. doi:10.1093/cid/cis966. PMID 23230301.

[pmid21208910-26] Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ; et al. (2011). "Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children". Clin Infect Dis. 52 (3): e18–55. doi:10.1093/cid/ciq146. PMID 21208910.

[pmid23591823-27] Sharff KA, Richards EP, Townes JM (2013). "Clinical management of septic arthritis". Curr Rheumatol Rep. 15 (6): 332. doi:10.1007/s11926-013-0332-4. PMID 23591823.

[28] "Clinical Management of Septic Arthritis" (PDF).

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

[17]

[18]

[19]

[20]

[21]

[22]

[23]

[24]

[25]

[26]

[27]

[28]

Sandbox ID Musculoskeletal: Difference between revisions

Revision as of 20:21, 28 July 2015

Contents

Bursitis

Osteomyelitis, candidal

Osteomyelitis, chronic

Osteomyelitis, contiguous with vascular insufficiency

Osteomyelitis, diabetic foot

Osteomyelitis, foot bone

Osteomyelitis, foot puncture wound

Osteomyelitis, hematogenous

Osteomyelitis, hemoglobinopathy

Osteomyelitis, spinal implant

Osteomyelitis, vertebral

Osteomyelitis, sternal

Osteonecrosis of the jaw

Reactive arthritis, post-streptococcal arthritis

Reactive arthritis, Reiter's syndrome

Septic arthritis, Brucella melitensis

Septic arthritis, candidal

Septic arthritis, gonococcal

Septic arthritis, Gram-negative bacilli

Septic arthritis, Histoplasmosis

Septic arthritis, Lyme disease

Septic arthritis, Mycobacterium tuberculosis

Septic arthritis, pneumococcal

Septic arthritis, post-intraarticular injection

Septic arthritis, prosthetic joint infection

Septic arthritis, staphylococcal

Septic arthritis, streptococcal

References

Navigation menu

@@ Line 11: / Line 11: @@
 * Osteomyelitis, candidal <ref name="pmid19191635">{{cite journal| author=Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE et al.| title=Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. | journal=Clin Infect Dis | year= 2009 | volume= 48 | issue= 5 | pages= 503-35 | pmid=19191635 | doi=10.1086/596757 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19191635  }} </ref>
 :* Preferred regimen: [[Fluconazole]] 400 mg (6 mg/kg) PO qd for 6–12 months {{or}} lipid formulation of [[Amphotericin B]] 3–5 mg/kg PO qd for several weeks, then [[Fluconazole]] for 6–12 months
 :* Alternative regimen (1):  [[Anidulafungin]] 200 mg loading dose, then 100 mg/day PO {{or}} [[Caspofungin]] 70mg loading dose, then 50 mg/day PO {{or}} [[Micafungin]] 100 mg/day PO, then [[Fluconazole]] for 6–12 months
 :* Alternative regimen (2): [[Amphotericin B]] deoxycholate 0.5–1 mg/kg PO qd for several weeks, then [[Fluconazole]] for 6–12 months
@@ Line 19: / Line 18: @@
 *Chronic Osteomyelitis in Adults – Pathogen-Based Therapy <ref name="pmid22157324">{{cite journal| author=Spellberg B, Lipsky BA| title=Systemic antibiotic therapy for chronic osteomyelitis in adults. | journal=Clin Infect Dis | year= 2012 | volume= 54 | issue= 3 | pages= 393-407 | pmid=22157324 | doi=10.1093/cid/cir842 | pmc=PMC3491855 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22157324  }} </ref>
 <ref name=Uptodate>{{cite web | url =http://www.uptodate.com/contents/search?search=chronic+osteomyelitis&sp=0&searchType=PLAIN_TEXT&source=USER_INPUT&searchControl=TOP_PULLDOWN&searchOffset= }}</ref>
+:*1. OSSA
-:*OSSA
 ::* Preferred regimen: [[Oxacillin]] 1.5–2 g IV q4h for 4–6 wk {{or}} [[Cefazolin]] 1–2 g IV q8h for 4–6 wk
 ::* Alternative regimen (1): [[Vancomycin]] 15 mg/kg IV q12h for 4–6 wk
 ::* Alternative regimen (2): [[Oxacillin]] 1.5–2 g IV q4h for 4–6 wk {{and}} [[Rifampin]] 600 mg PO qd
+:*2. ORSA
-:*ORSA
 ::* Preferred regimen: [[Vancomycin]] 15 mg/kg IV q12h for 4–6 wk {{or}} [[Daptomycin]] 6 mg/kg IV q24h
 ::* Alternative regimen (1): [[Linezolid]] 600 mg PO/IV q12h for 6 wk {{withorwithout}} [[Rifampin]] 600–900 mg PO qd
 ::* Alternative regimen (2): [[Levofloxacin]] 500–750 mg PO/IV daily {{withorwithout}} [[Rifampin]] 600–900 mg PO qd
-:*Penicillin-sensitive Streptococcus
+:*3. Penicillin-sensitive Streptococcus
 ::* Preferred regimen: [[Penicillin G]] 20 MU/day IV continuously or q4h for 4–6 wk {{or}} [[Ceftriaxone]] 1–2 g IV/IM q24h for 4–6 wk {{or}} [[Cefazolin]] 1–2 g IV q8h for 4–6 wk
 ::* Alternative regimen: [[Vancomycin]] 15 mg/kg IV q12h for 4–6 wk
+:*4. Enterococcus or Streptococcus (MIC≥0.5 μg/mL) or Abiotrophia or Granulicatella
-:*Enterococcus or Streptococcus (MIC≥0.5 μg/mL) or Abiotrophia or Granulicatella
+::* Preferred regimen: [[Penicillin G]] 20 MU/day IV continuously or q4h for 4–6 wk {{withorwithout}} [[Gentamicin]] 1 mg/kg IV/IM q8h for 1–2 wk {{or}} [[Ampicillin]] 12 g/day IV continuously or q4h for 4–6 wk {{withorwithout}} [[Gentamicin]] 1 mg/kg IV/IM q8h for 1–2 wk
-::* Preferred regimen: [[Penicillin G]] 20 MU/day IV continuously or q4h for 4–6 wk {{withorwithout}} [[Gentamicin]] 1 mg/kg IV or IM q8h for 1–2 wk {{or}} [[Ampicillin]] 12 g/day IV continuously or q4h for 4–6 wk {{withorwithout}} [[Gentamicin]] 1 mg/kg IV or IM q8h for 1–2 wk
+::* Alternative regimen: [[Vancomycin]] 15 mg/kg IV q12h for 4–6 wk {{withorwithout}} [[Gentamicin]] 1 mg/kg IV/IM q8h for 1–2 wk
+:*5. Enterobacteriaceae
-::* Alternative regimen: [[Vancomycin]] 15 mg/kg IV q12h for 4–6 wk {{withorwithout}} [[Gentamicin]] 1 mg/kg IV or IM q8h for 1–2 wk
-:*Enterobacteriaceae
 ::* Preferred regimen: [[Ceftriaxone]] 1–2 g IV/IM q24h for 4–6 wk {{or}} [[Ertapenem]] 1 g IV q24h
 ::* Alternative regimen: [[Levofloxacin]] 500–750 mg PO q24h {{or}} [[Ciprofloxacin]] 500–750 mg PO q12h for 4–6 wk
 :*Pseudomonas aeruginosa
-::* Preferred regimen: [[Cefepime]] 2 g IV q12h {{or}} [[Meropenem]] 1 g IV q8h {{or}} [[Imipenem]] 500 mg IV q6h for 4–6 wk
+::*6.  Preferred regimen: [[Cefepime]] 2 g IV q12h {{or}} [[Meropenem]] 1 g IV q8h {{or}} [[Imipenem]] 500 mg IV q6h for 4–6 wk
 ::* Alternative regimen: [[Ciprofloxacin]] 750 mg PO q12h {{or}} [[Ceftazidime]] 2 g IV q8h for 4–6 wk
@@ Line 48: / Line 42: @@
 :* ''Group A beta-hemolytic Streptococcus, Haemophilus influenzae type b, andStreptococcus pneumoniae''
 ::* Preferred regimen: [[Ampicillin]] 150–200 mg/kg/day administered in 4 equal doses {{or}} [[Amoxicillin]] 150–200 mg/kg/day administered in 4 equal doses
 ::* Alternative regimen: [[Chloramphenicol]] 75 mg/kg/day administered in 3 equal doses
@@ Line 54: / Line 47: @@
 * Osteomyelitis, contiguous with vascular insufficiency <ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
-:* Debride overlying ulcer and send bone specimen for histology and culture.
+:*Note (1): Debride overlying ulcer and send bone specimen for histology and culture.
-:* No empiric antimicrobial therapy unless acutely ill.
+:*Note (2): No empiric antimicrobial therapy unless acutely ill.
-:* Antibiotic therapy should be based on culture results and treat for 6 weeks.
+:*Note (3): Antibiotic therapy should be based on culture results and treat for 6 weeks.
-:* Revascularize if possible.
+:*Note (4): Revascularize if possible.
 ===Osteomyelitis, diabetic foot===
-* Chronic Infection or Recent Antibiotic Use <ref name="pmid23328846">{{cite journal| author=Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG et al.| title=2012 infectious diseases society of america clinical practice guideline for the diagnosis and treatment of diabetic foot infections. | journal=J Am Podiatr Med Assoc | year= 2013 | volume= 103 | issue= 1 | pages= 2-7 | pmid=23328846 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23328846  }} </ref>
+*1. Chronic Infection or Recent Antibiotic Use <ref name="pmid23328846">{{cite journal| author=Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG et al.| title=2012 infectious diseases society of america clinical practice guideline for the diagnosis and treatment of diabetic foot infections. | journal=J Am Podiatr Med Assoc | year= 2013 | volume= 103 | issue= 1 | pages= 2-7 | pmid=23328846 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23328846  }} </ref>
 :* Preferred regimen: [[Levofloxacin]] 750 mg IV/PO q24h {{or}} Cefoxitin 1 g IV q4h (or 2 g IV q6–8h) {{or}} [[Ceftriaxone]] 1–2 g/day IV/IM q12–24h {{or}} [[Ampicillin]]–Sulbactam 1.5–3 g IV/IM q6h {{or}} [[Moxifloxacin]] 400 mg IV/PO q24h {{or}} [[Ertapenem]] 1 g IV/IM q24h {{or}} [[Tigecycline]] 100 mg IV, then 50 mg IV q12h (active against MRSA) {{or}} [[Imipenem]]–Cilastatin 0.5–1 g IV q6–8h (Not active against MRSA; consider when ESBL-producing pathogens suspected)
 :* Alternative regimen (1): [[Levofloxacin]] 750 mg IV/PO q24h {{and}} [[Clindamycin]] 150–300 mg PO qid
 :* Alternative regimen (2): [[Ciprofloxacin]] 600–1200 mg/day IV q6–12h {{and}} [[Clindamycin]] 150–300 mg PO qid
 :* Alternative regimen (3): [[Ciprofloxacin]] 1200–2700 mg IV q6–12h (for more severe cases) {{and}} [[Clindamycin]] 150–300 mg PO qid
+*2. High Risk for MRSA
-* High Risk for MRSA
 :* Preferred regimen: [[Linezolid]] 600 mg IV/PO q12h {{or}} [[Daptomycin]] 4 mg/kg IV q24h {{or}} [[Vancomycin]] 15–20 mg/kg IV q8–12h (trough: 10–20 mg/L)
 * High Risk for ''Pseudomonas aeruginosa''
 :* Preferred regimen: [[Piperacillin–Tazobactam]] 3.375 g IV q6–8h
+*3. Polymicrobial Infection
-* Polymicrobial Infection
 :* Preferred regimen: ([[Vancomycin]] 15–20 mg/kg IV q8–12h (trough: 10–20 mg/L) {{or}} [[Linezolid]] 600 mg IV/PO q12h {{or}} [[Daptomycin]] 4 mg/kg IV q24h) {{and}} ([[Piperacillin–Tazobactam]] 3.375 g IV q6–8h {{or}} [[Imipenem]]–Cilastatin 0.5–1 g IV q6–8h {{or}} [[Ertapenem]] 1 g IV/IM q24h {{or}} [[Meropenem]] 1 g IV q8h)
 :* Alternative regimen: ([[Vancomycin]] 15–20 mg/kg IV q8–12h (trough: 10–20 mg/L) {{or}} [[Linezolid]] 600 mg IV/PO q12h {{or}} [[Daptomycin]] 4 mg/kg IV q24h) {{and}} ([[Ceftazidime]] 2 g IV q8h {{or}} [[Cefepime]] 2 g IV q8h {{or}} [[Aztreonam]] 2 g IV q6–8h) {{and}} [[Metronidazole]] 15 mg/kg IV, then 7.5 mg/kg IV q6h
@@ Line 92: / Line 78: @@
 :* Alternative regimen (2): [[Linezolid]] 600 mg IV/po bid<sup>NAI</sup> {{and}} [[Cefepime]]
-: NOTE: If susceptible Gm-neg. bacillus, [[Ciprofloxacin]] 750 mg po bid {{or}} [[Levofloxacin]] 750 mg po qd
+:* NOTE: If susceptible Gm-neg. bacillus, [[Ciprofloxacin]] 750 mg po bid {{or}} [[Levofloxacin]] 750 mg po qd
 ===Osteomyelitis, hematogenous===
-* Empiric therapy <ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
+*1. Empiric therapy <ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
-:* Adult (>21 yrs)
+:*1.1 Adult (>21 yrs)
-::* MRSA possible
+::*1.1.1 MRSA possible
 :::* Preferred regimen: [[Vancomycin]] 1 gm IV q12h (if over 100 kg, 1.5 gm IV q12h)
-::* MRSA unlikely
+::*1.1.2 MRSA unlikely
 :::* Preferred regimen: [[Nafcillin]] {{or}} [[Oxacillin]] 2 gm IV q4h
+:*1.2. Children (>4 mos.)-Adult
-:* Children (>4 mos.)-Adult
+::*1.2.1 MRSA possible
-::* MRSA possible
 :::* Preferred regimen: [[Vancomycin]] 40 div q6–8h
-::* MRSA unlikely
+::*1.2.2 MRSA unlikely
 :::* Preferred regimen: [[Nafcillin]] {{or}} [[Oxacillin]] 37 q6h (to max. 8–12 gm per day)
 ::* NOTE: Add [[Ceftazidime]] 50 q8h or [[Cefepime]] 150 div q8h if Gm-neg. bacilli on Gram stain
+:*1.3. Newborn (<4 mos.)
-:* Newborn (<4 mos.)
+::*1.3.1 MRSA possible
-::* MRSA possible
 :::* Preferred regimen: [[Vancomycin]] {{and}} ([[Ceftazidime]] 2 gm IV q8h or [[Cefepime]] 2 gm IV q12h)
-::* MRSA unlikely
+::*1.3.2 MRSA unlikely
 :::* Preferred regimen: ([[Nafcillin]] {{or}} Oxacillin) {{and}} ([[Ceftazidime]] {{or}} Cefepime)
+*2. Specific therapy
-* Specific therapy
+:*2.1 MSSA
-:* MSSA
 ::* Preferred regimen: [[Nafcillin]] {{or}} [[Oxacillin]] 2 gm IV q4h {{or}} [[Cefazolin]] 2 gm IV q8h
 ::* Alternative regimen: [[Vancomycin]] 1 gm IV q12h (if over 100 kg, 1.5 gm IV q12h)
-:* MRSA
+:*2.2 MRSA
 ::* Preferred regimen: [[Vancomycin]] 1 gm IV q12h
 ::* Alternative regimen: [[Linezolid]] 600 mg q12h IV/po {{withorwithout}} [[Rifampin]] 300 mg po/IV bid
 ===Osteomyelitis, hemoglobinopathy===
-* Osteomyelitis, hemoglobinopathy <ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
+*. Osteomyelitis, hemoglobinopathy <ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
 :* Preferred regimen: [[Ciprofloxacin]] 400 mg IV q12h
 :* Alternative regimen: [[Levofloxacin]] 750 mg IV q24h
 ===Osteomyelitis, spinal implant===
-* Onset within 30 days <ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
+*1. Onset within 30 days <ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
 :* Preferred regimen: Culture, treat & then suppress until fusion occurs
-* Onset after 30 days
+*2. Onset after 30 days
 :* Preferred regimen: Remove implant, culture & treat
@@ Line 138: / Line 120: @@
 * Vertebral Osteomyelitis – Pathogen-Based Therapy <ref name="pmid2024868">{{cite journal| author=Gentry LO| title=Oral antimicrobial therapy for osteomyelitis. | journal=Ann Intern Med | year= 1991 | volume= 114 | issue= 11 | pages= 986-7 | pmid=2024868 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2024868  }} </ref> <ref name="pmid21427393">{{cite journal| author=Marschall J, Bhavan KP, Olsen MA, Fraser VJ, Wright NM, Warren DK| title=The impact of prebiopsy antibiotics on pathogen recovery in hematogenous vertebral osteomyelitis. | journal=Clin Infect Dis | year= 2011 | volume= 52 | issue= 7 | pages= 867-72 | pmid=21427393 | doi=10.1093/cid/cir062 | pmc=PMC3106232 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21427393  }} </ref>
-:* OSSA or coagulase-negative staphylococci
+:*1. OSSA or coagulase-negative staphylococci
 ::* Preferred regimen: [[Oxacillin]] 2 g IV q6h {{or}} [[Cefazolin]] 1–2 g IV q8h
 ::* Alternative regimen: [[Levofloxacin]] 750 mg PO qd {{and}} [[Rifampin]] 300 mg PO bid
-:* ORSA
+:*2. ORSA
 ::* Preferred regimen: [[Vancomycin]] 1 g IV q12h
 ::* Alternative regimen (1): [[Daptomycin]] ≥ 6 mg/kg IV q24h
 ::* Alternative regimen (2): [[Levofloxacin]] 500–750 mg PO/IV daily {{and}} [[Rifampin]] 600–900 mg PO qd
-:* Streptococcus
+:*3. Streptococcus
 ::* Preferred regimen: [[Penicillin G]] 5 MU IV q6h
 ::* Alternative regimen: [[Ceftriaxone]] 2 g IV q24h
-:* Enterobacteriaceae, quinolone-susceptible
+:*4. Enterobacteriaceae, quinolone-susceptible
 ::* Preferred regimen: [[Ciprofloxacin]] 750 mg PO q12h
 ::* Alternative regimen: [[Ceftriaxone]] 2 g IV q24h
+:*5. Enterobacteriaceae, quinolone-resistant
-:* Enterobacteriaceae, quinolone-resistant
 ::* Preferred regimen: [[Imipenem]] 500 mg IV q6h
+:*6. Pseudomonas aeruginosa
-:* Pseudomonas aeruginosa
 ::* Preferred regimen: [[Cefepime]] 2 g IV q8h {{or}} [[Ceftazidime]] 2 g IV q8h x 2–4 wk, followed by [[Ciprofloxacin]] 750 mg PO bid
 ::* Alternative regimen: [[Piperacillin–Tazobactam]] 750 mg PO q12h x 2–4 wk, followed by [[Ciprofloxacin]] 750 mg PO bid
-:* Anaerobes
+:*7. Anaerobes
 ::* Preferred regimen: [[Piperacillin–Tazobactam]] 750 mg PO q12h x 2–4 wk, followed by [[Ciprofloxacin]] 750 mg PO bid
 ::* Alternative regimen (1): [[Penicillin G]] 5 MU IV q6h OR [[Ceftriaxone]] 2 g IV q24h (against gram-positive anaerobes)
 ::* Alternative regimen (2): [[Metronidazole]] 500 mg PO tid (against gram-negative anaerobes)
@@ Line 170: / Line 149: @@
 ===Osteonecrosis of the jaw===
-* Bacterial Infection <ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
+*1. Bacterial Infection <ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
 :* Preferred regimen:  Penicillin VK 500 mg PO q6–8h for 7–10 days (maintenance: 500 mg PO bid) {{or}} [[Amoxicillin]] 500 mg PO q8h for 7–10 days (maintenance: 500 mg PO bid)
 :* Alternative regimen: [[Clindamycin]] 150–300 mg PO qid {{or}} [[Doxycycline]] 100 mg PO qd {{or}} [[Erythromycin]] 400 mg PO tid {{or}} [[Azithromycin]] 500 mg PO for 1 dose, then 250 mg PO qd for 4 days {{or}} [[Levofloxacin]] 500 mg PO qd {{or}} [[Moxifloxacin]] 400 mg PO qd
-* Fungal Infection
+*2. Fungal Infection
 :* Preferred regimen: Nystatin oral suspension 5–15 mL swish qid {{or}} [[Fluconazole]] 200 mg PO qd, then 100 mg q24h {{or}} Clotrimazole 10 mg PO tid for 7–10 days
-* Viral Infection
+*3. Viral Infection
 :* Preferred regimen: [[Acyclovir]] 400 mg PO bid {{or}} [[Valacyclovir]] 0.5–2.0 g PO bid
@@ Line 196: / Line 172: @@
 ===Septic arthritis, candidal===
 * Septic arthritis, candidal <ref name="pmid19191635">{{cite journal| author=Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE et al.| title=Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. | journal=Clin Infect Dis | year= 2009 | volume= 48 | issue= 5 | pages= 503-35 | pmid=19191635 | doi=10.1086/596757 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19191635  }} </ref>
+:* Preferred regimen: [[Fluconazole]] 400 mg (6 mg/kg) daily for at least 6 weeks {{or}} lipid formulation of [[Amphotericin B]] 3–5 mg/kg daily for several weeks, then [[Fluconazole]] to completion
-:* Preferred regime: [[Fluconazole]] 400 mg (6 mg/kg) daily for at least 6 weeks {{or}} lipid formulation of [[Amphotericin B]] 3–5 mg/kg daily for several weeks, then [[Fluconazole]] to completion
+:* Alternative regimen: [[Anidulafungin]] 200-mg loading dose, then 100 mg/day {{or}} [[Caspofungin]] 70-mg loading dose, then 50 mg/day {{or}} [[Micafungin]] 100 mg/day {{or}} [[Amphotericin B]] deoxycholate 0.5–1 mg/kg daily for several weeks then [[Fluconazole]] to completion
-:* Alternative regime: [[Anidulafungin]] 200-mg loading dose, then 100 mg/day {{or}} [[Caspofungin]] 70-mg loading dose, then 50 mg/day {{or}} [[Micafungin]] 100 mg/day {{or}} [[Amphotericin B]] deoxycholate 0.5–1 mg/kg daily for several weeks then [[Fluconazole]] to completion
 :* NOTE: Duration of therapy usually is for at least 6 weeks, but few data are available; Surgical debridement is recommended for all cases; For infected prosthetic joints, removal is recommended for most cases.
 ===Septic arthritis, gonococcal===
 * Septic arthritis, gonococcal <ref name="pmid12364368">{{cite journal| author=Shirtliff ME, Mader JT| title=Acute septic arthritis. | journal=Clin Microbiol Rev | year= 2002 | volume= 15 | issue= 4 | pages= 527-44 | pmid=12364368 | doi= | pmc=PMC126863 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12364368  }} </ref>
-:* Preferred regime: [[Ceftriaxone]] 1 g intramuscularly IM/IV every 24 h
+:* Preferred regimen: [[Ceftriaxone]] 1 g intramuscularly IM/IV every 24 h
-:* Alternative regime: [[Cefotaxime]] 1 g IV every 8 hours {{or}} [[Ceftizoxime]] 1 g IV every 8 hours
+:* Alternative regimen: [[Cefotaxime]] 1 g IV every 8 hours {{or}} [[Ceftizoxime]] 1 g IV every 8 hours
 :* NOTE: The tetracyclines (except in pregnant women) or penicillins may be used if the infecting organism is proven to be susceptible; Penicillin allergies should be given Spectinomycin (2 g IV every 12 h);Alternative antibiotics in the β-lactam-allergic patient may be [[Ciprofloxacin]] (500 mg IV every 12 h) or [[Ofloxacin]] (400 mg IV every 12 h)
-:* Pediatric regime: (>45 kg) single daily dose of [[Ceftriaxone]] (50 mg/kg and a maximum dose of 2 g, IM or IV) for 10 to 14 days; (<45 kg) [[Ceftriaxone]] (50 mg/kg and a maximum dose of 1 g, IM or IV in a single daily dose for 7 days)
+:* Pediatric regimen: (>45 kg) single daily dose of [[Ceftriaxone]] (50 mg/kg and a maximum dose of 2 g, IM or IV) for 10 to 14 days; (<45 kg) [[Ceftriaxone]] (50 mg/kg and a maximum dose of 1 g, IM or IV in a single daily dose for 7 days)
 ===Septic arthritis, Gram-negative  bacilli===
 * Septic arthritis, Gram-negative  bacilli <ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2015 | isbn = 978-1930808843 }}</ref>
-:* Preferred regime: [[Ceftazidime]] 2 g IV q8h {{or}} [[Cefepime]] 2 g IV q8–12h {{or}} [[Piperacillin-Tazobactam]] 4.5 g IV q6h
+:* Preferred regimen: [[Ceftazidime]] 2 g IV q8h {{or}} [[Cefepime]] 2 g IV q8–12h {{or}} [[Piperacillin-Tazobactam]] 4.5 g IV q6h
+:* Alternative regimen: [[Aztreonam]] 2 g IV q8h {{or}} [[Imipenem]] 500 mg IV q6h {{or}} [[Meropenem]] 1 g IV q8h {or}} [[Doripenem]] 500 mg IV q8h {{or}} [[Carbapenems]]
-:* Alternative regime: [[Aztreonam]] 2 g IV q8h {{or}} [[Imipenem]] 500 mg IV q6h {{or}} [[Meropenem]] 1 g IV q8h {or}} [[Doripenem]] 500 mg IV q8h {{or}} [[Carbapenems]]
 ===Septic arthritis, Histoplasmosis===
 * Septic arthritis, histoplasmosis<ref name="pmid17806045">{{cite journal| author=Wheat LJ, Freifeld AG, Kleiman MB, Baddley JW, McKinsey DS, Loyd JE et al.| title=Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. | journal=Clin Infect Dis | year= 2007 | volume= 45 | issue= 7 | pages= 807-25 | pmid=17806045 | doi=10.1086/521259 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17806045  }}</ref>
-:* Mild disease
+:*1. Mild disease
 ::* Preferred regimen: [[Nonsteroidal anti-inflammatory drug]]
+:*2. Severe disease
-:* Severe disease
 ::* Preferred regimen: [[Prednisone]] 0.5–1.0 mg/kg/day (maximum: 80 mg daily) in tapering doses over 1–2 weeks {{and}} [[Itraconazole]] 200 mg tid for 3 days, followed by qd or bid for 6–12 weeks
 ===Septic arthritis, Lyme disease===
 * Septic arthritis, Lyme disease <ref name="pmid17029130">{{cite journal| author=Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS et al.| title=The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. | journal=Clin Infect Dis | year= 2006 | volume= 43 | issue= 9 | pages= 1089-134 | pmid=17029130 | doi=10.1086/508667 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17029130  }} </ref>
-:* Patients without clinical evidence of neurologic disease
+:*1. Patients without clinical evidence of neurologic disease
-::* Preferred regime: [[Doxycycline]] 100 mg twice per day {{or}} [[Amoxicillin]] 500 mg 3 times per day {{or}} [[Cefuroxime Axetil]] 500 mg twice per day for 28 days
+::* Preferred regimen: [[Doxycycline]] 100 mg twice per day {{or}} [[Amoxicillin]] 500 mg 3 times per day {{or}} [[Cefuroxime Axetil]] 500 mg twice per day for 28 days
-::* Pediatric regime: [[Amoxicillin]] 50 mg/kg per day in 3 divided doses maximum of 500 mg per dose {{or}} [[Cefuroxime Axetil]] 30 mg/kg per day in 2 divided doses maximum of 500 mg per dose {{or}} (if the patient is ≥8 years of age) [[Doxycycline]] 4 mg/ kg per day in 2 divided doses (maximum of 100 mg per dose)
+::* Pediatric regimen: [[Amoxicillin]] 50 mg/kg per day in 3 divided doses maximum of 500 mg per dose {{or}} [[Cefuroxime Axetil]] 30 mg/kg per day in 2 divided doses maximum of 500 mg per dose {{or}} (if the patient is ≥8 years of age) [[Doxycycline]] 4 mg/ kg per day in 2 divided doses (maximum of 100 mg per dose)
-:* Patients with arthritis and objective evidence of neurologic disease
+:*2. Patients with arthritis and objective evidence of neurologic disease
-::* Preferred regime: [[Ceftriaxone]] administered parenterally for 2–4 weeks
+::* Preferred regimen: [[Ceftriaxone]] administered parenterally for 2–4 weeks
-::* Alternative regime: [[Cefotaxime]] {{or}} [[Penicillin G]] administered parenterally
+::* Alternative regimen: [[Cefotaxime]] {{or}} [[Penicillin G]] administered parenterally
-::* Pediatric regime: [[Ceftriaxone]] {{or}} [[Cefotaxime]] {{or}} [[Penicillin G]] administered intravenously
+::* Pediatric regimen: [[Ceftriaxone]] {{or}} [[Cefotaxime]] {{or}} [[Penicillin G]] administered intravenously
 :* NOTE (1): For patients who have persistent or recurrent joint swelling after a recommended course of oral antibiotic therapy, we recommend re-treatment with another 4-week course of oral antibiotics or with a 2–4-week course of [[Ceftriaxone]] IV
 :* NOTE (2): If patients have no resolution of arthritis despite intravenous therapy and if PCR results for a sample of synovial fluid (and synovial tissue if available) are negative, symptomatic treatment is recommended, which consist of nonsteroidal anti-inflammatory agents, intra-articular injections of corticosteroids, or disease-modifying antirheumatic drugs (DMARDs), such as Hydroxychloroquine.
@@ Line 238: / Line 211: @@
 * Septic arthritis, Mycobacterium  tuberculosis<ref>{{Cite book| edition = 4th| publisher = World Health Organization| isbn = 9789241547833| title = Treatment of Tuberculosis: Guidelines| location = Geneva| series = WHO Guidelines Approved by the Guidelines Review Committee| accessdate = 2015-06-08| date = 2010| url = http://www.ncbi.nlm.nih.gov/books/NBK138748/| pmid = 23741786}}</ref>
+:*1. Septic arthritis caused by susceptible Mycobacterium tuberculosis
-:* Septic arthritis caused by susceptible Mycobacterium tuberculosis
+::*1.1 '''Adults'''
-::* '''Intensive phase (adult)'''
+:::*1.1.1 '''Intensive phase'''
-:::* Preferred regimen: [[Isoniazid]] 5 mg/kg (max: 300 mg) for 2 months {{and}} [[Rifampin]] 10 mg/kg (max: 600 mg) for 2 months {{and}} [[Pyrazinamide]] 15–30 mg/kg (max: 2 g) for 2 months {{and}} [[Ethambutol]] 15–20 mg/kg (max: 1 g) for 2 months
+::::* Preferred regimen: [[Isoniazid]] 5 mg/kg (max: 300 mg) for 2 months {{and}} [[Rifampin]] 10 mg/kg (max: 600 mg) for 2 months {{and}} [[Pyrazinamide]] 15–30 mg/kg (max: 2 g) for 2 months {{and}} [[Ethambutol]] 15–20 mg/kg (max: 1 g) for 2 months
+:::*1.1.2 '''Continuation phase'''
-::* '''Continuation phase (adult)'''
+::::* Preferred regimen: [[Isoniazid]] 5 mg/kg (max: 300 mg) for 7 months {{and}} [[Rifampin]] 10 mg/kg (max: 600 mg) for 7 months
-:::* Preferred regimen: [[Isoniazid]] 5 mg/kg (max: 300 mg) for 7 months {{and}} [[Rifampin]] 10 mg/kg (max: 600 mg) for 7 months
+::*1.2 '''Pediatric'''
+:::*1.2.1 '''Intensive phase'''
-::* '''Intensive phase (pediatric)'''
+::::* Preferred regimen: [[Isoniazid]] 10–15 mg/kg (max: 300 mg) for 2 months {{and}} [[Rifampin]] 10–20 mg/kg (max: 600 mg) for 2 months {{and}} [[Pyrazinamide]] 15–30 mg/kg (max: 2 g) for 2 months {{and}} [[Ethambutol]] 15–20 mg/kg (max: 1 g) for 2 months
-:::* Preferred regimen: [[Isoniazid]] 10–15 mg/kg (max: 300 mg) for 2 months {{and}} [[Rifampin]] 10–20 mg/kg (max: 600 mg) for 2 months {{and}} [[Pyrazinamide]] 15–30 mg/kg (max: 2 g) for 2 months {{and}} [[Ethambutol]] 15–20 mg/kg (max: 1 g) for 2 months
+:::*1.2.2 '''Continuation phase'''
+::::* Preferred regimen: [[Isoniazid]] 10–15 mg/kg (max: 300 mg) for 7 months {{and}} [[Rifampin]] 10–20 mg/kg (max: 600 mg) for 7 months
-::* '''Continuation phase (pediatric)'''
+:*2. Specific considerations
-:::* Preferred regimen: [[Isoniazid]] 10–15 mg/kg (max: 300 mg) for 7 months {{and}} [[Rifampin]] 10–20 mg/kg (max: 600 mg) for 7 months
+::*2.1 '''Pregnancy and breastfeeding'''
-:* Specific considerations
-::* '''Pregnancy and breastfeeding'''
 :::* With the exception of streptomycin, the first line anti-TB drugs are safe for use in pregnancy: [[Streptomycin]] is ototoxic to the fetus and should not be used during pregnancy.
 :::* After active TB in the baby is ruled out, the baby should be given 6 months of isoniazid preventive therapy, followed by BCG vaccination.
 :::* Pyridoxine supplementation is recommended for all pregnant or breastfeeding women taking isoniazid.
+::*2.2 '''Liver disorders'''
-::* '''Liver disorders'''
 :::* Two hepatotoxic drugs (rather than the three in the standard regimen):
 ::::* 9 months of [[Isoniazid]] {{and}} [[Rifampicin]] {{and}} [[Ethambutol]] (until or unless [[Isoniazid]] susceptibility is documented).
@@ Line 265: / Line 234: @@
 :::* One hepatotoxic drug:
 ::::* 2 months of [[Isoniazid]] {{and}} [[Ethambutol]] {{and}} [[Streptomycin}}, followed by 10 months of [[Isoniazid]] {{and}} [[Ethambutol]].
 :::* No hepatotoxic drugs:
 ::::* 18–24 months of [[Streptomycin]] {{and}} [[Ethambutol]] {{and}} a [[Fluoroquinolone]].
+::*2.3 '''Renal failure and severe renal insufficiency'''
-::* '''Renal failure and severe renal insufficiency'''
 :::* The recommended initial TB treatment regimen for patients with renal failure or severe renal insufficiency is 2 months of isoniazid, rifampicin, pyrazinamide and ethambutol, followed by 4 months of isoniazid and rifampicin.
 :::* There is significant renal excretion of ethambutol and metabolites of pyrazinamide, and doses should therefore be adjusted.
@@ Line 275: / Line 242: @@
 :::* While receiving isoniazid, patients with severe renal insufficiency or failure should also be given pyridoxine in order to prevent peripheral neuropathy.
 :::* Because of an increased risk of nephrotoxicity and ototoxicity, [[Streptomycin]] should be avoided in patients with renal failure. If [[Streptomycin]] must be used, the dosage is 15 mg/kg, two or three times per week, to a maximum of 1 gram per dose, and serum levels of the drug should be monitored.
+::*2.4 '''Previously treated patients in settings with rapid DST'''
-::* '''Previously treated patients in settings with rapid DST'''
 :::* TB patients whose treatment has failed or other patient groups with high likelihood of multidrug-resistant TB (MDR) should be started on an empirical MDR regimen.
 :::* TB patients returning after defaulting or relapsing from their first treatment course may receive the retreatment regimen containing first-line drugs 2HRZES/1HRZE/5HRE if country-specific data show low or medium levels of MDR in these patients or if such data are not available.
+::*2.5 '''TB treatment in people living with HIV'''
-::* '''TB treatment in people living with HIV'''
 :::* TB patients with known positive HIV status and all TB patients living in HIV prevalent settings should receive daily TB treatment at least during the intensive phase.
 :::* For the continuation phase, the optimal dosing frequency is also daily for these patients.
@@ Line 295: / Line 260: @@
 * Septic arthritis, prosthetic joint infection (device-related osteoarticular infections) <ref name="pmid23230301">{{cite journal| author=Osmon DR, Berbari EF, Berendt AR, Lew D, Zimmerli W, Steckelberg JM et al.| title=Executive summary: diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. | journal=Clin Infect Dis | year= 2013 | volume= 56 | issue= 1 | pages= 1-10 | pmid=23230301 | doi=10.1093/cid/cis966 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23230301  }} </ref>
-:* Empiric antimicrobial therapy
+:*1. Empiric antimicrobial therapy
 ::* It is preferable to delay antibiotic therapy until specimens for culture are obtained by joint aspiration, joint debridement, and/or prosthesis removal.
+:*2. Pathogen-directed antimicrobial therapy
-:* Pathogen-directed antimicrobial therapy
+::*2.1 Staphylococcus aureus, methicillin-susceptible (MSSA)
-::* Staphylococcus aureus, methicillin-susceptible (MSSA)
 :::* Preferred regimen: [[Nafcillin]] 2 g IV q4–6h {{or}} [[Oxacillin]] 2 g IV q4–6h
 :::* Alternative regimen: [[Cefazolin]] 1–2 g IV q8h {{or}} [[Ceftriaxone]] 2 g IV q24h
 :::* Alternative regimen (if allergic to penicillins): [[Clindamycin]] 900 mg IV q8h {{or}} [[Vancomycin]] 15–20 mg/kg IV q8–12 hours, not to exceed 2 g per dose
+::*2.2 Staphylococcus, methicillin-resistant (MRSA)
-::* Staphylococcus, methicillin-resistant (MRSA)
+:::*2.2.1 Early-onset (&lt; 2 months after surgery) or acute hematogenous prosthetic joint infections involving a stable implant with short duration (< 3 weeks) of symptoms and debridement (but device retention)
-:::* Early-onset (&lt; 2 months after surgery) or acute hematogenous prosthetic joint infections involving a stable implant with short duration (< 3 weeks) of symptoms and debridement (but device retention)
 ::::* Preferred regimen: [[Vancomycin]] {{and}} [[Rifampin]] 600 mg PO qd or 300–450 mg PO bid for 2 weeks
 ::::* Alternative regimen: ([[Daptomycin]] 6 mg/kg IV q24h {{or}} [[Linezolid]] 600 IV q8h) {{and}} [[Rifampin]] 600 mg PO qd or 300–450 mg PO bid for 2 weeks
-::::: Note: The above regimen should be followed by [[Rifampin]] plus a fluoroquinolone, TMP/SMX, a tetracycline or [[Clindamycin]] for 3 or 6 months for hips and knees, respectively.
+::::* Note: The above regimen should be followed by [[Rifampin]] plus a fluoroquinolone, TMP/SMX, a tetracycline or [[Clindamycin]] for 3 or 6 months for hips and knees, respectively.
+:::*2.2.2 Early-onset spinal implant infections (&lt; 30 days after surgery), or implants in an actively infected site
-:::* Early-onset spinal implant infections (&lt; 30 days after surgery), or implants in an actively infected site
 ::::* Initial parenteral therapy plus [[Rifampin]] followed by prolonged oral therapy is recommended.
 ::::* Long-term oral suppressive antibiotics (eg, TMP-SMX, a tetracycline, a fluoroquinolone [which should be given in conjunction with [[Rifampin]] due to the potential emergence of fluoroquinolone resistance)
+::*2.3 Streptococci, beta-hemolytic
-::* Streptococci, beta-hemolytic
 :::* Preferred regimen: [[Penicillin]] 12–18 MU/day IV q6h {{or}} [[Ampicillin]] 2 g IV q6h {{or}} [[Ceftriaxone]] 1–2 g IV q24h
 :::* Alternative regimen (allergic to penicillin): [[Clindamycin]] 900 mg IV q8h {{or}} [[Vancomycin]] 15–20 mg/kg q8–12h, not to exceed 2 g per dose
+::*2.4 Enterococci
-::* Enterococci
+:::*2.4.1 Monotherapy
-:::* Monotherapy
 ::::* Preferred regimen (1): [[Ampicillin]] 6 to 12 g per 24 hours in four to six equally divided doses
 ::::* Preferred regimen (2): [[Penicillin G]] 18 to 30 million units per 24 hours either continuously or in six equally divided doses
 ::::* Preferred regimen (3): [[Vancomycin]] 15 to 20 mg/kg/dose every 8 to 12 hours, not to exceed 2 g per dose
+:::*2.4.2 Combination therapy (one of the monotherapy agents, and one of the following agents)
-:::* Combination therapy (one of the monotherapy agents, and one of the following agents)
 ::::* Preferred regimen (1): [[Gentamicin]] 1 mg/kg IV q8h
 ::::* Preferred regimen (2): [[Streptomycin]] 7.5 mg/kg IV q12h
 ::::* Preferred regimen (3): [[Ampicillin]] 2 g/day IV q6h {{and}} [[Ceftriaxone]] 2 g IV q12h
+::*2.5 Gram-negative bacilli
-::* Gram-negative bacilli
 :::* Patients susceptible to fluoroquinolones
 ::::* Preferred regimen: [[Ciprofloxacin]] 500 to 750 mg bid
-:::* ''P. aeruginosa''
+:::*2.5.1 ''P. aeruginosa''
 ::::* Preferred regimen: [[Cefepime]] 2 g intravenously every 12 hours {{or}} [[Meropenem]] 1 g intravenously every 8 hours
 ::::* Alternative regimen (1): [[Ciprofloxacin]] 750 mg orally every 12 hours [[Ceftazidime]] 2 g intravenously every 8 hours (alternative)
 ::::* Alternative regimen (2): [[Ceftazidime]] 2 g intravenously every 8 hours
+::*2.6 Anaerobes
-::* Anaerobes
+:::*2.6.1''Propionibacterium acnes''
-::''Propionibacterium acnes''
+::::* Preferred regimen: [[Penicillin]] 24 million units intravenously every 24 hours given in six equally divided doses or as continuous infusion {{or}} [[Ceftriaxone]] 1 to 2 g intravenously once daily
-:::* Preferred regimen: [[Penicillin]] 24 million units intravenously every 24 hours given in six equally divided doses or as continuous infusion {{or}} [[Ceftriaxone]] 1 to 2 g intravenously once daily
+::::* Alternative regimen: [[Vancomycin]] {{or}} Clindamycin
-:::* Alternative regimen: [[Vancomycin]] {{or}} Clindamycin
+:::*2.6.2 Not ''Propionibacterium acnes''
-:: Not ''Propionibacterium acnes''
 :::* Preferred regimen: [[Metronidazole]] 500 mg orally three times a day.
+::*2.7 Mycobacterium tuberculosis
-::* Mycobacterium tuberculosis
 :::* Preferred regimen: see (Septic arthritis, Mycobacterium tuberculosis)
+::*2.8 Fungi
-::* Fungi
 :::* Preferred regimen: see (Septic arthritis, candidal)
+::*2.9 Culture negative
-::* Culture negative
 :::* Preferred regimen:  [[Vancomycin]] {{and}} [[Ciprofloxacin]] {{or}} [[Cefazolin]] {{and}} [[Ciprofloxacin]]
 ===Septic arthritis, staphylococcal===
-''Staphylococcus aureus (methicillin-resistant)'' <ref name="pmid21208910">{{cite journal| author=Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ et al.| title=Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. | journal=Clin Infect Dis | year= 2011 | volume= 52 | issue= 3 | pages= e18-55 | pmid=21208910 | doi=10.1093/cid/ciq146 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21208910  }} </ref><ref name="pmid23591823">{{cite journal| author=Sharff KA, Richards EP, Townes JM| title=Clinical management of septic arthritis. | journal=Curr Rheumatol Rep | year= 2013 | volume= 15 | issue= 6 | pages= 332 | pmid=23591823 | doi=10.1007/s11926-013-0332-4 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23591823  }} </ref><ref name=name of the journal>{{cite web | title = topic name and journal name| url =http://www.uptodate.com/contents/septic-arthritis-in-adults?source=search_result&search=Septic+arthritis&selectedTitle=1~150#H18 }}</ref>
+*1.''Staphylococcus aureus (methicillin-resistant)'' <ref name="pmid21208910">{{cite journal| author=Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ et al.| title=Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. | journal=Clin Infect Dis | year= 2011 | volume= 52 | issue= 3 | pages= e18-55 | pmid=21208910 | doi=10.1093/cid/ciq146 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21208910  }} </ref><ref name="pmid23591823">{{cite journal| author=Sharff KA, Richards EP, Townes JM| title=Clinical management of septic arthritis. | journal=Curr Rheumatol Rep | year= 2013 | volume= 15 | issue= 6 | pages= 332 | pmid=23591823 | doi=10.1007/s11926-013-0332-4 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23591823  }} </ref><ref name=name of the journal>{{cite web | title = topic name and journal name| url =http://www.uptodate.com/contents/septic-arthritis-in-adults?source=search_result&search=Septic+arthritis&selectedTitle=1~150#H18 }}</ref>
 :* Preferred regime: [[Vancomycin]] 15–20 mg/kg IV q8–12h
 :* Alternative regimen (1): [[Daptomycin]] 6 mg/kg IV q24h in adults
 :* Alternative regimen (2): [[Linezolid]] 600 mg PO/IV q12h
 :* Alternative regimen (3): [[Clindamycin]] 600 mg PO/IV q8h
 :* Alternative regimen (4): TMP-SMX 3.5–4.0 mg/kg PO/IV q8–12h
+:* Pediatric regimen: [[Vancomycin]] 15 mg/kg IV q6h {{or}} [[Daptomycin]] 6–10 mg/kg IV q24h {{or}} [[Linezolid]] 10 mg/kg PO/IV q8h {{or}} [[Clindamycin]] 10–13 mg/kg/dose PO/IV q6–8h
-:* Pediatric regime: [[Vancomycin]] 15 mg/kg IV q6h {{or}} [[Daptomycin]] 6–10 mg/kg IV q24h {{or}} [[Linezolid]] 10 mg/kg PO/IV q8h {{or}} [[Clindamycin]] 10–13 mg/kg/dose PO/IV q6–8h
+. ''Staphylococcus aureus (methicillin-susceptible)''
+:* Preferred regimen: [[Nafcillin]] 2 g IV q6h OR [[Clindamycin]] 900 mg IV q8h
-''Staphylococcus aureus (methicillin-susceptible)''
+:* Alternative regimen: [[Cefazolin]] 0.25–1 g IV/IM q6–8h {{or}} [[Vancomycin]] 500 mg IV q6h or 1 g IV q12h
-:* Preferred regime: [[Nafcillin]] 2 g IV q6h OR [[Clindamycin]] 900 mg IV q8h
+. ''Staphylococcus epidermidis (methicillin-resistant)''
-:* Alternative regime: [[Cefazolin]] 0.25–1 g IV/IM q6–8h {{or}} [[Vancomycin]] 500 mg IV q6h or 1 g IV q12h
+:* Preferred regimen: [[Vancomycin]] 500 mg IV q6h or 1 g IV q12h {{or}} [[Linezolid]] 600 mg IV q12h
+:* Alternative regimen: TMP-SMX 3.5–4.0 mg/kg PO/IV q8–12h (TMP component) {{or}} Minocycline 200 mg PO x 1 dose, then 100 mg PO q12h {{and}} [[Rifampin]] 300–600 mg PO/IV q12h
-''Staphylococcus epidermidis (methicillin-resistant)''
+. ''Staphylococcus epidermidis (methicillin-susceptible)''
-:* Preferred regime: [[Vancomycin]] 500 mg IV q6h or 1 g IV q12h {{or}} [[Linezolid]] 600 mg IV q12h
+:* Preferred regimen: [[Nafcillin]] 2 g IV q6h OR [[Clindamycin]] 900 mg IV q8h
-:* Alternative regime: TMP-SMX 3.5–4.0 mg/kg PO/IV q8–12h (TMP component) {{or}} Minocycline 200 mg PO x 1 dose, then 100 mg PO q12h {{and}} [[Rifampin]] 300–600 mg PO/IV q12h
+:* Alternative regimen: [[Cefazolin]] 0.25–1 g IV/IM q6–8h {{or}} [[Vancomycin]] 500 mg IV q6h or 1 g IV q12h
-''Staphylococcus epidermidis (methicillin-susceptible)''
-:* Preferred regime: [[Nafcillin]] 2 g IV q6h OR [[Clindamycin]] 900 mg IV q8h
-:* Alternative regime: [[Cefazolin]] 0.25–1 g IV/IM q6–8h {{or}} [[Vancomycin]] 500 mg IV q6h or 1 g IV q12h
 ===Septic arthritis, streptococcal===
-''Streptococcus agalactiae'' <ref>{{cite web | title = Clinical Management of Septic Arthritis| url =http://www.med.unc.edu/tarc/events/event-files/septic%20arthritis%20management.pdf }}</ref>
+. ''Streptococcus agalactiae'' <ref>{{cite web | title = Clinical Management of Septic Arthritis| url =http://www.med.unc.edu/tarc/events/event-files/septic%20arthritis%20management.pdf }}</ref>
-:* Preferred regime: [[Penicillin G]] 2 MU IV/IM q4h {{or}} [[Ampicillin]] 2 g IV q6h
+:* Preferred regimen: [[Penicillin G]] 2 MU IV/IM q4h {{or}} [[Ampicillin]] 2 g IV q6h
+:* Alternative regimen: [[Clindamycin]] 600–1200 mg/day IV/IM q6–12h {{or}} [[Cefazolin]] 0.25–1 g IV/IM q6–8h
-:* Alternative regime: [[Clindamycin]] 600–1200 mg/day IV/IM q6–12h {{or}} [[Cefazolin]] 0.25–1 g IV/IM q6–8h
+. ''Streptococcus pyogenes''
-''Streptococcus pyogenes''
+:* Preferred regimen: [[Penicillin G]] 2 MU IV/IM q4h {{or}} [[Ampicillin]] 2 g IV q6h
-:* Preferred regime: [[Penicillin G]] 2 MU IV/IM q4h {{or}} [[Ampicillin]] 2 g IV q6h
+:* Alternative regimen: [[Clindamycin]] 600–1200 mg/day IV/IM q6–12h {{or}} [[Cefazolin]] 0.25–1 g IV/IM q6–8h
-:* Alternative regime: [[Clindamycin]] 600–1200 mg/day IV/IM q6–12h {{or}} [[Cefazolin]] 0.25–1 g IV/IM q6–8h
 ==References==
 {{reflist|2}}

Sandbox ID Musculoskeletal: Difference between revisions

Revision as of 20:21, 28 July 2015

Bursitis

Osteomyelitis, candidal

Osteomyelitis, chronic

Osteomyelitis, contiguous with vascular insufficiency

Osteomyelitis, diabetic foot

Osteomyelitis, foot bone

Osteomyelitis, foot puncture wound

Osteomyelitis, hematogenous

Osteomyelitis, hemoglobinopathy

Osteomyelitis, spinal implant

Osteomyelitis, vertebral

Osteomyelitis, sternal

Osteonecrosis of the jaw

Reactive arthritis, post-streptococcal arthritis

Reactive arthritis, Reiter's syndrome

Septic arthritis, Brucella melitensis

Septic arthritis, candidal

Septic arthritis, gonococcal

Septic arthritis, Gram-negative bacilli

Septic arthritis, Histoplasmosis

Septic arthritis, Lyme disease

Septic arthritis, Mycobacterium tuberculosis

Septic arthritis, pneumococcal

Septic arthritis, post-intraarticular injection

Septic arthritis, prosthetic joint infection

Septic arthritis, staphylococcal

Septic arthritis, streptococcal

References

Navigation menu

Search